MedTrace Logo

Platelet-Rich Plasma for Partial Rotator Cuff Tears

NCT07659600 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-06-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether platelet-rich plasma (PRP) injection, made from a participant's own blood, can help heal the tendon and improve shoulder symptoms in people with partial tears of the supraspinatus tendon.

The main questions it aims to answer are:

* Does PRP help the tendon heal?
* Does PRP improve pain, shoulder movement, daily function, and shoulder magnetic resonance imaging (MRI) findings?

Researchers will compare PRP plus standard of care (physical therapy) to standard of care alone to see if PRP leads to better healing and better clinical results. Researchers will also study if differences in specific biomolecules in PRP are associated with differences in treatment response.

Participants will:

* receive standard of care treatment, with or without PRP injection depending on the study group
* have blood collected for PRP preparation
* have their pain, shoulder movement, and shoulder function assessed
* undergo shoulder MRI scans
* be followed over time to measure healing and symptom improvement

Conditions

  • Partial Supraspinatus Tear
  • Rotator Cuff Tears (RCTs)
  • Rotator Cuff Injury

Interventions

BIOLOGICAL

Platelet-Rich Plasma (PRP) Injections

Autologous leucocyte-poor platelet-rich plasma prepared from peripheral blood collected on the day of treatment and administered as a single ultrasound-guided percutaneous injection at or near the partial supraspinatus tendon tear, in addition to standard rehabilitation care. PRP is processed by centrifugation and a residual sample is reserved for cellular and molecular characterization

Sponsors & Collaborators

  • Hospital da Luz, Portugal

    collaborator OTHER

  • Universidade Nova de Lisboa

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2029-06-01
Completion
2029-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07659600 on ClinicalTrials.gov